Mutation Specific Kinase activity Measurements

Profiling Kinase Conformations

KinCon biolabs is a R&D project of the Institute of Biochemistry at the University of Innsbruck.
We are creating unique biosensors for improved kinase-inhibitor development

Our luciferase based reporter measures drug-driven effects on kinase-activity by reflecting changes of cellular kinase-conformations.

This technology allows reliable profiling of potential kinase-inhibitors under physiological conditions:

  • Direct measurement in living cells
  • Cancer drug profiling in real-time 
  • Simple integration of patient mutations for precision medicine


Meet the people working to provide you with new tools to assess kinase drug efficacy.

Philipp Tschaikner

Project management

Florian Enzler


Eduard Stefan

Scientific Advisor

Rainer Schneider

Scientific Advisor


Catch up with our latest News

We welcome Philipp Raffeiner who will work on novel Cdk4/6 KinCon reporters in the following months.

With December 1st we started with the execution of proof-of-concept studies to prove the practical suitability and marketability of our KinCon biosensors to accelerate kinase inhibitor development.

KinCon biolabs was selected to receive the ‘FFG Spin-off Fellowship’, a funding Programme by the Austrian Research Promotion Agency (FFG). 


Recent Publications in which the KinCon technology is applied

Contact Us

KinCon biolabs

Institute of Biochemistry
University of Innsbruck
Center for Chemistry and Biomedicine (CCB)
Innrain 80-82
6020 Innsbruck

Tel.: +43 512 507 57535

KinCon biolabs is funded and supported by the University of Innsbruck and the  Austrian Research Promotion Agency (FFG)